One of the main challenges in targeting V-ATPase is its ubiquitous expression and essential role in normal cellular functions, which raises concerns about potential toxicity and side effects. Selective inhibitors that specifically target the V-ATPase isoforms or subunits overexpressed in cancer cells need to be developed to minimize adverse effects on normal tissues.
